<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03275454</url>
  </required_header>
  <id_info>
    <org_study_id>TNT009-201</org_study_id>
    <secondary_id>TNT009-201</secondary_id>
    <nct_id>NCT03275454</nct_id>
  </id_info>
  <brief_title>A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose TNT009 in Participants With Chronic Immune Thrombocytopenia (ITP)</brief_title>
  <official_title>The Safety, Tolerability, and Pharmacokinetics &amp; Pharmacodynamics of Multiple- Dose TNT009 in Patients With Chronic Immune Thrombocytopenia (ITP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioverativ Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioverativ Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the safety, preliminary clinical benefit, and
      activity of TNT009 in patients with chronic immune thrombocytopenia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2017</start_date>
  <completion_date type="Anticipated">May 2, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Time from first dose to the final study visit, assessed up to approximately 13 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. A serious adverse event (SAE) is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Premature Study Terminations</measure>
    <time_frame>Up to Day 91</time_frame>
    <description>Number of participants with premature study terminations will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinical Laboratory Abnormalities</measure>
    <time_frame>Up to Day 91</time_frame>
    <description>Clinical laboratory abnormalities included hematology, clinical chemistry panel, coagulation safety panel, urinalysis, and antibodies against platelet antigens.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Complete response (CR)</measure>
    <time_frame>Baseline to end of treatment (9 weeks)</time_frame>
    <description>Complete response per Evidence Practice Guidelines for Immune Thrombocytopenia: a platelet count greater than or equal to (&gt;=) 100*10^9 per liter measured on 2 occasions at least 7 days apart and the absence of bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Response (R)</measure>
    <time_frame>Baseline to end of treatment (9 weeks)</time_frame>
    <description>Response: A platelet count &gt;= 30*10^9 per liter and a greater than 2-fold increase from baseline measured on 2 occasions at least 7 days apart and the absence of bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With No Response (NR)</measure>
    <time_frame>Baseline to end of treatment (9 weeks)</time_frame>
    <description>No response (NR): A platelet count less than (&lt;) 30*10^9 per liter, or a less than two-fold increase from baseline, or the presence of bleeding. Platelet count must be measured on 2 occasions more than 1 day apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Loss of Complete Response</measure>
    <time_frame>Baseline to end of treatment (9 weeks)</time_frame>
    <description>Loss of complete response: A platelet count &lt; 100*10^9 per liter measured on 2 occasions more than 1 day apart and/ or the presence of bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Loss of Response</measure>
    <time_frame>Baseline to end of treatment (9 weeks)</time_frame>
    <description>Loss of response: A platelet count &lt; 30*10^9 per liter, or a less than 2-fold increase in platelet count from baseline, or the presence of bleeding. Platelet count must be measured on 2 occasions more than 1 day apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of TNT009</measure>
    <time_frame>Up to Day 91</time_frame>
    <description>Plasma concentrations of TNT009 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of TNT009</measure>
    <time_frame>Up to Day 91</time_frame>
    <description>Maximum observed concentration of TNT009 in plasma will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of TNT009</measure>
    <time_frame>Up to Day 91</time_frame>
    <description>Time to Reach Maximum Observed Plasma Concentration (Tmax) of TNT009 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC) From Hour 0 Over the Dosing Interval (AUC[0-tau]) of TNT009</measure>
    <time_frame>Up to Day 91</time_frame>
    <description>Area Under the Concentration-time Curve (AUC) From Hour 0 Over the Dosing Interval (AUC[0-tau]) of TNT009 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-drug antibodies (ADAs) Against TNT009</measure>
    <time_frame>Up to Day 91</time_frame>
    <description>Blood samples will be collected to determine number of participants with anti-drug antibodies (ADAs) against TNT009.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complement System Classical Pathway Levels as Measured by WIESLAB Assay</measure>
    <time_frame>Up to Day 91</time_frame>
    <description>Inhibition by TNT009 of the complement system classical pathway measured by the WIESLAB assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Complement (CH50) Levels</measure>
    <time_frame>Up to Day 91</time_frame>
    <description>Complement CH50 is a blood test that helps us determine whether protein abnormalities and deficiencies in the complement system are responsible for any increase in autoimmune activity. It will be assessed using complement assays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Complement Factor C4 Levels</measure>
    <time_frame>Up to Day 91</time_frame>
    <description>Total C4 Levels will be assessed in plasma using complement assays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C1 Complex Components: C1q and C1s Levels</measure>
    <time_frame>Up to Day 91</time_frame>
    <description>C1q and C1s Levels will be assessed in plasma using complement assays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Autoantibodies Against Platelet Antigens (GPIIb/IIIa and GPIb/IX)</measure>
    <time_frame>Up to Day 91</time_frame>
    <description>Autoantibodies against platelet antigens (GPIIb/IIIa and GPIb/IX) will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Purpura, Thrombocytopenic, Idiopathic</condition>
  <arm_group>
    <arm_group_label>TNT009</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a fixed dose intravenous (IV) infusion of 5.5 grams TNT009 on Days 0, 7, 21, 35 and 49.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNT009</intervention_name>
    <description>Participants will receive TNT009 5.5 grams as IV infusion.</description>
    <arm_group_label>TNT009</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic ITP refractory to standard therapy as defined in the protocol

          -  Normal prothrombin time (PT/INR) and activated partial thromboplastin time (aPTT)

          -  No history of a coagulation disorder

          -  Hemoglobin level greater than (&gt;) 10 gram per deciliter (g/dL) (following blood
             transfusion is acceptable) and normal white blood cell (WBC) and neutrophil counts
             (elevated WBC/absolute neutrophil count [ANC] attributed to steroid treatment is
             acceptable)

          -  Eastern Cooperative Oncology Group (ECOG) performance status grade less than or equal
             to (&lt;=) 2

          -  Previously vaccinated against encapsulated bacterial pathogens (Neisseria
             meningitidis, Meningitis B, Haemophilus influenzae, and Streptococcus pneumoniae) or
             willing to undergo vaccination. Reimmunization with meningococcal conjugate is
             required if the last vaccination was &gt; 5 years prior to enrollment

          -  Adequate intravenous (IV) access

        Exclusion Criteria:

          -  Clinically significant medical history or ongoing chronic illness that would
             jeopardize the safety of the participant or compromise the quality of the data derived
             from his/her participation in this study

          -  Clinically relevant infection of any kind within the preceding month of enrollment

          -  History of venous or arterial thrombosis within the preceding year of enrollment

          -  Use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), or anticoagulants
             within 1 week of enrollment

          -  History of lupus or other autoimmune disorder associated with antinuclear antibodies
             (ANAs) at screening

          -  Secondary immune thrombocytopenia from any cause including lymphoma, chronic
             lymphocytic leukemia, and drug-induced thrombocytopenia

          -  Positive hepatitis panel (including hepatitis B surface antigen and/or hepatitis C
             virus antibody) prior to or at Screening

          -  Positive human immunodeficiency virus (HIV) antibody prior to or at Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bioverativ Therapeutics Inc, Waltham, MA, USA</last_name>
    <phone>1-888-794-1415</phone>
    <email>clinicaltrials@bioverativ.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Georgetown Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Georgetown</city>
        <state>Washington</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>September 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2017</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autoimmune Diseases</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Blood Platelet Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

